Edition:
United States

ContraFect Corp (CFRX.OQ)

CFRX.OQ on NASDAQ Stock Exchange Capital Market

0.93USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,359
52-wk High
$2.50
52-wk Low
$0.80

Chart for

About

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin... (more)

Overall

Beta: --
Market Cap(Mil.): $69.23
Shares Outstanding(Mil.): 73.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 190.77 15.47
EPS (TTM): -- -- --
ROI: -- -11.61 33.71
ROE: -- -35.87 16.38

BRIEF-ContraFect announces Q3 loss per share $0.02

* ContraFect Corp - ‍As of Sept 30, 2017, had cash, cash equivalents and marketable securities of $52.6 million compared to $35.2 million as of December 31, 2016​ Source text for Eikon: Further company coverage:

Nov 09 2017

Earnings vs. Estimates